Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: J Clin Pharmacol. 2022 Sep 11;63(1):105–118. doi: 10.1002/jcph.2139

Table 2.

Median Percent Change from Baseline SLE Biomarkers, Belimumab 10 mg/kg IV

DNA Antibody Complement C4 CD20+
Adult22 (Furie)a −49.5 +51.9 −54.8
Adult23 (Navarra) –37.6 +30.4 --
Pediatric21 (Brunner) −44.9 +50 −65.8
a

Biomarkers assessed at week 76, all others at week 52

IV, intravenous; SLE, systemic lupus erythematosus